Imaging AI in Wisconsin

Imaging Biometrics develops quantitative medical imaging analysis software focused on neuro-oncology and brain tumor characterization. The company specializes in advanced post-processing algorithms and plugins that enhance MRI interpretation, particularly for contrast-enhanced imaging and perfusion analysis. Core product offerings include FTB Maps (for tumor characterization), IB Nimble (clinical workflow integration), IB Neuro (neuroimaging analysis with Delta T1 and rCBV mapping), IB Diffusion, IB DCE (dynamic contrast-enhanced imaging), IB Delta Suite, IB Rad Tech, and IB StoneChecker. The software leverages proprietary quantitative technology including Delta T1 (standardized T1 subtraction) and relative cerebral blood volume (rCBV) mapping to improve accuracy in assessing residual enhancing tumors, differentiating sellar lesions, and guiding surgical and therapeutic management. Products are designed for PACS compatibility and clinical implementation in hospital radiology departments and neuro-oncology centers. The company serves academic medical centers, community hospitals, and research institutions internationally, with particular strength in European and North American markets. Imaging Biometrics emphasizes clinical validation through peer-reviewed publications and collaborations with academic neuroradiologists and neuro-oncologists. Software is available as Mac plugins with free trial and demonstration options. The company maintains direct clinical support and works with institutional research teams on imaging-guided surgical planning and radiation therapy applications.

EnsoData is a healthcare technology company specializing in AI-powered software solutions for sleep medicine diagnostics and management. Founded in 2015 and based in Madison, Wisconsin, the company develops FDA-cleared cloud-based platforms that automate sleep study scoring and analysis using machine learning to process polysomnography (PSG) and home sleep apnea test (HSAT) waveforms. EnsoData's integrated ecosystem—comprising EnsoHST (multi-night home sleep testing device), EnsoSleep (AI-assisted scoring and analysis), EnsoHub (centralized study management platform), and Therapy Track (long-term therapy monitoring)—enables sleep clinics to streamline workflows, reduce diagnostic turnaround times, and improve clinical accuracy. The platform has processed over 2.8 million studies and impacted more than 2.5 million patients. EnsoData serves 500+ sleep clinics globally and achieves 97% patient success rates with >92% sensitivity for obstructive sleep apnea detection. The company's solutions address scalability challenges in sleep medicine and expand access to diagnosis for the estimated 425 million patients worldwide with undiagnosed sleep disorders.

AIQ Solutions develops TRAQinform IQ, a FDA-cleared (510(k) K233998) software medical device for quantitative assessment of treatment response heterogeneity in late-stage cancer patients. The platform analyzes serial radiographic images (PET, CT) to measure change in lesion regions of interest over time, providing oncologists with novel quantitative and spatial information to optimize therapy selection and clinical outcomes. TRAQinform IQ measures intra-patient heterogeneity through metrics such as SUVhetero, which has demonstrated superior prognostication of overall survival compared to standard-of-care methods (RECIST, PERCIST, global SUVpeak, global volume) in retrospective studies of metastatic lung cancer and lymphoma. The software integrates into existing clinical workflows via HIPAA-compliant cloud-based image upload and automated report generation. Primary users are oncologists and clinicians managing patients with metastatic and castration-resistant prostate cancer, metastatic lung cancer, and lymphoma. The company received a new Category III CPT code for lesion heterogeneity assessment. AIQ Solutions operates US offices in Madison, Wisconsin, and an international office in Perth, Australia through the Harry Perkins Institute of Medical Research.

UltraGreen.ai is a global leader in fluorescence-guided surgery and surgical intelligence solutions. The company develops an integrated ecosystem combining indocyanine green (ICG) fluorescence pharmaceuticals, near-infrared imaging hardware, AI-powered quantification software, and cloud-based data analytics platforms for real-time surgical decision-making. UltraGreen's technology stack includes IC-Green®/Verdye™ (indocyanine green), IC-Flow™ compact handheld NIR cameras, PerfusionWorks™ AI-driven quantification software, and UltraGreen Data Systems cloud platform for capturing and analyzing surgical outcomes. Approved and distributed in 28+ countries with regulatory exemptions in 40+ markets, the company serves surgeons across general surgery, vascular, oncology, and other specialties, with operations spanning North America, Europe, and Southeast Asia.

Promega Corporation is a global life science reagent and instrument manufacturer specializing in assays, reagents, and detection systems for research, drug discovery, clinical diagnostics, and forensic applications. The company develops bioluminescent reporter systems (NanoLuc® Luciferase, firefly luciferase), qPCR and RT-qPCR master mixes (GoTaq® systems), cell viability and apoptosis assays (CellTiter-Glo®, Caspase-Glo®), kinase selectivity profiling platforms (NanoBRET® systems), and imaging instrumentation (GloMax® Galaxy bioluminescence imager). Primary markets include small-molecule drug discovery, cell and gene therapy development, clinical research and molecular diagnostics, human identification (forensic DNA analysis), and academia. Manufacturing and R&D operations in Madison, Wisconsin are ISO 9001 (Quality Management Systems) and ISO 14001:2015 (Environmental Management Systems) certified. Products are manufactured under stringent quality control standards suitable for regulated clinical and diagnostic applications. Technical support and customer service resources include protocols, certificates of analysis, safety data sheets, and dedicated technical services scientists. The company serves pharmaceutical, biotech, clinical laboratory, forensic, and academic research markets globally.